Form 4 for TXG 10x Genomics, Inc.
Accepted 2026-08-28 19:22:30 ET · period of report 2026-08-26 · accession 0001610717-26-000393 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-08-28 19:22 | 2026-08-26 | TXG | Saxonov Serge | CEO, Dir | S - Sale | $63.69 | -10.5K | 1.08M | -1.0% | -$667.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-08-26 | S | D | 3,500 | $63.02 | 1,082,335 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $62.53 to $63.50, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Class A Common Stock | 2026-08-26 | S | D | 6,494 | $63.98 | 1,075,841 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. (F3) This transaction was executed in multiple trades at prices ranging from $63.56 to $64.54, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 3 | Common | Class A Common Stock | 2026-08-26 | S | D | 492 | $64.75 | 1,075,349 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. (F4) This transaction was executed in multiple trades at prices ranging from $64.59 to $64.99, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |